115 related articles for article (PubMed ID: 36272941)
1. Assessing the proportion of patients with hepatitis C treated before and after initiation of an ambulatory pharmacist-led hepatitis C program: A retrospective analysis.
Ortiz J; Rasch M
J Am Pharm Assoc (2003); 2023; 63(1):440-446. PubMed ID: 36272941
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
3. Pharmacist-initiated hepatitis C virus screening in a community pharmacy to increase awareness and link to care at the medical center.
Isho NY; Kachlic MD; Marcelo JC; Martin MT
J Am Pharm Assoc (2003); 2017; 57(3S):S259-S264. PubMed ID: 28506379
[TBL] [Abstract][Full Text] [Related]
4. Pharmacist-driven multidisciplinary pretreatment workup process for hepatitis C care: A novel model for same-day pretreatment workup.
Houck KK; Ifeachor AP; Fleming BS; Andres AM; O'Donovan KN; Johnson AJ; Liangpunsakul S
J Am Pharm Assoc (2003); 2019; 59(5):710-716. PubMed ID: 31227418
[TBL] [Abstract][Full Text] [Related]
5. Pharmacist engagement within a hepatitis C ambulatory care clinic in the era of a treatment revolution.
Gauthier TP; Moreira E; Chan C; Cabrera A; Toro M; Carrasquillo MZ; Corentin M; Sherman EM
J Am Pharm Assoc (2003); 2016; 56(6):670-676. PubMed ID: 27667501
[TBL] [Abstract][Full Text] [Related]
6. Innovating the Model for Student Pharmacists to Increase Access to Hepatitis C Testing (Project IMPACT).
Januszka J; Notarianni V; Devenny E; Harris E
J Am Pharm Assoc (2003); 2023; 63(4):1217-1221. PubMed ID: 37037394
[TBL] [Abstract][Full Text] [Related]
7. Impact of embedding a pharmacist in a dermatology clinic on outcomes in a specialty pharmacy.
Penick T; Hawkins T; O'Reilly E; Maniyar H; Maier C; McPheeters C
J Am Pharm Assoc (2003); 2023; 63(2):661-666. PubMed ID: 36464555
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Dillon JF
BMJ Open; 2018 Dec; 8(12):e021443. PubMed ID: 30552244
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of pharmacist care delivery models for hepatitis C clinics.
Naidjate SS; Zullo AR; Dapaah-Afriyie R; Hersey ML; Marshall BDL; Winkler RM; Berard-Collins C
Am J Health Syst Pharm; 2019 May; 76(10):646-653. PubMed ID: 30873537
[TBL] [Abstract][Full Text] [Related]
10. Implementation of hepatitis C screening within a pharmacist-managed medication-assisted therapy opioid use disorder protocol program.
Llayton CK; Harlow CP; Burris JN; Rhodes J
J Am Pharm Assoc (2003); 2020; 60(6):e307-e311. PubMed ID: 32527703
[TBL] [Abstract][Full Text] [Related]
11. Pharmacist-led drug therapy management for hepatitis C at a federally qualified health care center.
Downes JM; Donovan A; McAdam-Marx C
J Am Pharm Assoc (2003); 2022; 62(5):1596-1605. PubMed ID: 35595639
[TBL] [Abstract][Full Text] [Related]
12. Interprofessional Collaboration Between a Clinical Pharmacist and Specialty Physicians to Treat Hepatitis C in an Interdisciplinary Medical Practice Setting.
Fix JT; Hauf S; Herrera M; Martin R; Sweeden M; Meyer K
J Pharm Technol; 2022 Dec; 38(6):335-342. PubMed ID: 36311306
[No Abstract] [Full Text] [Related]
13. A Regional Analysis of Hepatitis C Virus Collaborative Care With Pharmacists in Indian Health Service Facilities.
Geiger R; Steinert J; McElwee G; Carver J; Montanez R; Niewoehner J; Clark C; Reilley B
J Prim Care Community Health; 2018; 9():2150132718807520. PubMed ID: 30348039
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Pharmacist-Led Treatment of Hepatitis C in the Virginia Department of Corrections.
Masuda QN; Smith JE; Gaines J; Dillingham RA
J Correct Health Care; 2023 Dec; 29(6):430-438. PubMed ID: 37943532
[TBL] [Abstract][Full Text] [Related]
15. Developing a multidisciplinary HCV direct-acting antivirals utilization management and assessment program.
Ajlan AA; Al-Gain R; Ahmed M; Abu-Riash T; Alquaiz M; Alkhail FA; Alashgar H; Alkhairallah T; Alkortas D; Al-Jedai A
J Am Pharm Assoc (2003); 2021; 61(2):e159-e170. PubMed ID: 33309191
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacy programmatic perspectives on use of direct-acting antivirals for acquired hepatitis C infection in solid organ transplant recipients.
Crona L; Berry H; Byrns J; Campbell U
Am J Health Syst Pharm; 2020 Jul; 77(14):1149-1152. PubMed ID: 32537658
[TBL] [Abstract][Full Text] [Related]
17. Patient Access to Hepatitis C Treatment After Incorporation of Pharmacists in a Hepatology Clinic.
Fanizza FA; Loucks J; Berni A; Shah M; Grauer D; Daniel S
Hosp Pharm; 2022 Jun; 57(3):370-376. PubMed ID: 35615482
[No Abstract] [Full Text] [Related]
18. Outcomes of a Pharmacist-Led Hepatitis C Virus Treatment Program in an Urban Safety-Net Health System, Chicago, 2017-2019.
Hunt BR; Cetrone H; Sam S; Glick NR
Public Health Rep; 2022; 137(4):702-710. PubMed ID: 34043923
[TBL] [Abstract][Full Text] [Related]
19. Patient satisfaction with the clinical pharmacist and prescribers during hepatitis C virus management.
Martin MT; Faber DM
J Clin Pharm Ther; 2016 Dec; 41(6):645-649. PubMed ID: 27578276
[TBL] [Abstract][Full Text] [Related]
20. DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy.
Radley A; Tait J; Dillon JF
Int J Drug Policy; 2017 Sep; 47():126-136. PubMed ID: 28647161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
